Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Total Non-Current Liabilities (2020 - 2026)

Cogent Biosciences' Total Non-Current Liabilities history spans 6 years, with the latest figure at $295.3 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 355.65% to $295.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $295.3 million through Mar 2026, up 355.65% year-over-year, with the annual reading at $301.2 million for FY2025, 320.6% up from the prior year.
  • Total Non-Current Liabilities came in at $295.3 million for Q1 2026, down from $301.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $301.2 million in Q4 2025 to a low of $43.4 million in Q4 2022.
  • The 4-year median for Total Non-Current Liabilities is $117.4 million (2025), against an average of $145.0 million.
  • Year-over-year, Total Non-Current Liabilities skyrocketed 192.13% in 2022 and then surged 355.65% in 2026.
  • Cogent Biosciences' Total Non-Current Liabilities stood at $43.4 million in 2022, then soared by 65.1% to $71.6 million in 2024, then soared by 320.6% to $301.2 million in 2025, then decreased by 1.98% to $295.3 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Total Non-Current Liabilities are $295.3 million (Q1 2026), $301.2 million (Q4 2025), and $121.1 million (Q3 2025).